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Abstract
The introduction of Haemophilus influenzae type b (Hib) vaccine into the Danish childhood vaccination programme in 1993 may have
influenced the epidemiology of H. influenzae meningitis (i.e. increasing frequency of other non-vaccine types; presentation in other age
groups). Based on nationwide registration, clinical information and laboratory findings were collected from all 65 confirmed cases of
H. influenzae meningitis during the period 1994–2005. Twenty-nine patients (45%) were <13 years old [median 15 months (range
0–147)], and 36 patients (55%) were >24 years old [median 62 years (range 25–96)]. Hib accounted for 31% (20/65) of the cases, and
significantly more children were infected with Hib compared with adults [53% (16/29) vs. 11% (4/36), respectively, p 0.0003]. Overall,
38% of cases had an otogenic focus and this was thus the most frequent primary focus of infection. Among children infected with Hib,
two cases (13%) were identified as true vaccine failures. Six patients (9%) died; one premature infant infected with serotype f and five
adults (age 83–96 years) with non-typeable H. influenzae. Hearing loss was reported in 16% of the surviving children and in 10% of the
surviving adults. The presence of a lung focus was an independent prognostic factor for an unfavourable outcome (p 0.03). In conclu-
sion, meningitis caused by Hib has been infrequent in Denmark after introduction of the Hib vaccine in the childhood vaccination pro-
gramme, and no increase in meningitis cases due to non-b type H. influenzae has been observed. Cases with H. influenzae meningitis
frequently had an otogenic focus, with low risk of an unfavourable outcome.
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Introduction
Haemophilus influenzae type b (Hib) has been the leading
cause of childhood meningitis, but the introduction of the
Hib vaccine (ActHib; Sanofi Pasteur MSD, Bruxelles, Bel-
gium) into the Danish childhood vaccination programme in
1993, and concurrently in most industrialized countries, has
virtually eliminated the disease in these countries [1–4].
According to estimates made by the WHO, by the end of
2007 >122 countries had introduced the vaccine in their
childhood vaccination programmes [5]. However, introduc-
tion of widespread vaccination may change the epidemiology
of the disease, i.e. changes in the presentation of the disease
(e.g. increased incidence among age groups other than chil-
dren [6], changes in morbidity and mortality), which may be
related to alteration in population immunity [7] and/or
increased number of cases with other capsular serotypes
due to serotype replacement. Indeed, several studies have
reported an increased frequency of invasive H. influenzae
infections from non-vaccine serotypes [8–12]. Therefore, the
aim of the present study was to investigate clinical and para-
clinical characteristics of all cases with H. influenzae meningi-
tis in Denmark during the period 1994–2005.
Materials and Methods
Patients
Purulent meningitis, including meningitis due to H. influenzae,
is a notifiable disease in Denmark. Accordingly, the treating
physician is required to report all cases of purulent meningitis
to the Department of Epidemiology, Statens Serum Institut.
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However, an evaluation of the notification system has previ-
ously shown that only two-thirds of all cases are reported
[13,14]. To obtain information on non-notified cases we
therefore requested all clinical microbiology departments in
Denmark to provide information on all positive cultures from
cerebrospinal fluid (CSF) and concomitant blood cultures
during the same period. Thus, the study represents a nation-
wide collection of consecutive cases of H. influenzae meningi-
tis during the period 1 January 1994 to 31 December 2005.
Data collection
Clinical and laboratory information is provided via the treat-
ing physician notification form, i.e. diagnosis, time of onset of
symptoms, clinical features, vaccination status, time of lumbar
puncture, and the results of CSF microscopy and CSF/blood
culture. Hospital discharge records concerning all reported
cases were prospectively collected. The medical records of
identified cases, when possible, were collected retrospec-
tively, providing laboratory data and additional information
on radiological examinations, clinical course and outcome of
the disease, as well as results from follow-up audiological
examinations. In addition, all admission and discharge
records, including date of death, were subsequently con-
firmed in the Danish civil registration database and in the
national hospital registration database (Grønne system).
Definitions
Haemophilus influenzae meningitis was defined as a positive
CSF microscopy/culture with H. influenzae or CSF pleocyto-
sis (‡10 white blood cells/mL) in conjunction with a positive
blood culture of H. influenzae.
Focus of infection was determined according to the clinical
diagnosis made by the physician and was confirmed by radi-
ography (pneumonia), computed tomography (sinusitis, mas-
toiditis), or magnetic resonance scanning. Otogenic focus
was confirmed by a specialist otological examination. Micro-
biological isolation of the pathogen from the presumed focus
of infection was not deemed necessary.
Vaccination status of children in age groups eligible for
vaccination according to the Danish National Childhood Vac-
cination Programme was provided by the patient’s general
practitioner (GP). A vaccine failure was defined according to
the definition of Booy et al. [15]. True vaccine failure was
defined as Hib meningitis occurring either >1 week after a
child up to the age of 12 months received at least two doses
of the Hib vaccine, or >2 weeks after a single dose was
received by a child >12 months of age. Cases of Hib meningi-
tis occurring after receipt of one or two doses of vaccine,
and before sufficient time had elapsed to be counted as true
vaccine failure, were defined as apparent vaccine failure. Out-
come: mortality was recorded as death due to meningitis
during hospitalization. Hearing sequelae were determined by
an otologist upon follow-up audiological examination after
discharge from the hospital. Neurological sequelae were
determined upon post-discharge follow-up examination. An
unfavourable outcome was defined as death or the presence
of sequelae.
Ethics
The study was approved by the local scientific ethics com-
mittee and the Danish Data Protection Agency (no. 2006-
41-7066).
Statistics
All data are presented as medians and interquartile ranges.
Comparisons among groups were performed using the
Mann–Whitney test for continuous data and the Fisher Exact
test for categorical data. Logistic regression analysis was
employed for calculating the relative risk of an unfavourable
outcome. Only variables with >80% of values available and
with a p value £0.2 were tested in the multivariate analysis.
p <0.05 was considered statistically significant.
Results
Identification of patients
A total of 65 patients with meningitis due to H. influenzae
were included in the study; 51 of these cases were notified
during the period 1 January 1994 to 31 December 2005.
One case, despite not fulfilling the study definition of menin-
gitis (i.e. no CSF data were available due to failure of lumbar
puncture), was included because the patient had typical clini-
cal signs of meningitis (nuchal rigidity and impaired con-
sciousness) upon admission, had growth of H. influenzae in a
blood culture, and was successfully treated for meningitis.
Fourteen non-notified cases (11 adults and three children)
were identified, based on information provided by Danish
departments of clinical microbiology.
Demographic characteristics
Fig. 1 shows the annual number of H. influenzae meningitis
cases in Denmark during the period 1994–2005 (Danish pop-
ulation size, c. 5.2 million inhabitants). Approximately 60
cases per year, predominantly due to Hib, were reported
during the pre-vaccination period, 1980–1993 [4,16]. Thus,
the vaccination programme appeared to result in a 12-fold
decrease in the annual incidence rate (c. 0.1 vs. c. one case
per 100 000 persons). As expected, there was a significant
reduction in the number of cases with Hib (fewer than one
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case per year during the period 1994–2005), whereas no
alteration in the number of cases with non-Hib was observed
with vaccination (approximately four cases per year). Among
the 65 cases included in the study, 29 were children
<13 years of age, and 36 were adults ‡25 years of age. No
cases were observed in the age group 13–24 years. A total
of 45 cases were due to non-Hib (69%), whereas 20 cases
were due to Hib (31%). A significantly higher frequency of
Hib was found in children than in adults [53% (16/29) vs.
11% (4/36), respectively, p 0.0003]. This was in accordance
with the findings from the period before 1993, when only a
limited number of cases of Hib meningitis were adults [16].
The median age for adult cases with Hib meningitis was
40 years (30.5–54.0) compared with non-type b meningitis,
which was 63.5 years (47.5–76.5, p 0.07), and the median
age in children (p 0.5) was 13.5 months (5.0–25.0) for Hib
meningitis and 16 months (6.0–48.0) for non-Hib meningitis.
Vaccination status. Table 1 shows the vaccination status of
the 28 children included in the study (data on vaccination
were not available for one case). A total of 12 children had
received one or more vaccine dose prior to the meningitis
episode, whereas 16 children and all adult cases were unvac-
cinated. Among the 12 vaccinated children, five cases were
due to Hib, and four of these cases were identified as
vaccine failures (two true vaccine failures and two apparent
vaccine failures). Among the 16 unvaccinated children, ten
cases contracted Hib meningitis.
Patient characteristics
Clinical features of both child and adult cases are shown in
Table 2. Since the identified pathogen was closely related to
age groups, as described above, comparison between cases
with Hib or non-Hib meningitis was made only among children
(see Table 3); no such analysis was performed among adults
due to a limited number of adult cases with Hib (n = 4).
Predisposing conditions. Predisposing conditions were found in
22% (13/60) of cases, and all 13 cases with predisposing con-
ditions were among the non-Hib meningitis cases [children:
non-Hib 38% (5/13) vs. Hib 0% (0/16), respectively, p 0.01].
Among these 13 cases, seven were iatrogenic (four cases
after neurocranial surgery; three after surgery for sinusitis,
mastoiditis or cholesteatoma), five patients had a history of
head trauma and one patient had a tympanic membrane
defect of unknown origin.
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FIG. 1. Number of cases with Haemo-
philus influenzae meningitis in Denmark
1994–2005. Haemophilus influenzae
meningitis cases due to type b (white)
and type non-b (black)
TABLE 1. Vaccination status and serotypes of Haemophilus
influenzae meningitis among children
No. of doses Type ba Type non-b
0 10 6
1 2 0
2 2 4
3 1 3
Total 15 13
aNo data were available for one case.
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Underlying disease. While none of the children had an under-
lying disease, five adults (17%) had an underlying disease
[cancer (n = 3), diabetes mellitus (n = 2)]. All five adults
were infected with non-Hib.
Focus of infection. Otitis media was the most frequent pri-
mary focus of infection and was present in 38% (25/65) of all
cases. Five of these patients also had mastoiditis. Pneumonia
and sinusitis were present in 12% (8/65) and 8% (5/65) of
cases, respectively, whereas the focus of infection was
unknown in 47% (30/65) of cases. The focus of infection was
not significantly associated with the age group of the patient.
However, children infected with Hib more frequently had an
unknown focus when compared with children infected with
non-Hib [63% (10/16) vs. 23% (3/13), respectively, p 0.06].
Prehospital diagnostic and therapeutic management. A GP was
consulted prior to hospitalization in 42% (26/62) of cases.
Children had significantly increased frequency of fever prior
to hospitalization compared with adults (72% vs. 31%,
respectively, p 0.001). Prior to admission, 24% (14/58) of
patients had received antibiotic treatment with a b-lactam
[therapy with phenoxymethylpenicillin and aminopenicillins in
71% (10/14) and 29% (4/14) of cases, respectively], and all of
the H. influenzae strains isolated from these patients
appeared to be ampicillin susceptible (13/14; no susceptibility
testing data were available for one case).
Clinical characteristics. Meningitis was the tentative diagnosis
of the admitting physician in 86% (55/64) of cases. Upon
admission, classical signs of purulent meningitis were present
in a majority of patients, and 92% of patients (59/63)
received a lumbar puncture on the day of admission. Fever
was present in 88% (46/52) of patients, back rigidity in 75%
(43/57), and an altered mental status in 72% (42/58) (ranging
from decreased responsiveness or confusion to coma). Con-
vulsions occurred in 19% of cases (11/57) and more fre-
quently in children [30% (8/27) than in adults 10% (3/30) (p
TABLE 2. Clinical characteristics of
Haemophilus influenzae meningitis
according to age groups
Percentage or medians (25/75 percentiles) Adults (n = 36) Children (n = 29) p-value
Gender (females, %) 63% (23/36) 46% (13/29) 0.14
Age 63 years (44–75) 15 months (5–28)
Infected with Hib 11% (4/36) 53% (16/29) 0.0003
Underlying diseases 17% (5/30) 0% (0/29) 0.05
Predisposing conditions 26% (8/31) 17% (5/29) 0.54
Focus of infection
Otitis media 33% (12/36) 45% (13/29) 0.44
Pneumonia 17% (6/36) 7% (2/29) 0.28
Sinusitis 8% (3/36) 7% (2/29) 1.0
Unknown 47% (17/36) 45% (13/29) 1.0
Examined by a physician before admission 38% (13/34) 46% (13/28) 0.61
Duration of symptoms before admission 2 days (2–3) 2 days (1–5) 0.89
Received antibiotics before admission 22% (7/32) 27% (7/26) 0.76
Fever before admission 31% (11/36) 72% (21/29) 0.001
Clinical features on admission
Fever (temp. >38C) 82% (23/28) 96% (23/24) 0.20
Body temperature 39.1C (38.2–39.7) 39.5C (38.9–40.0) 0.06
Back rigidity 79% (27/34) 70% (16/23) 0.53
Altered mental status 67% (22/33) 80% (20/25) 0.38
Convulsions 10% (3/30) 30% (8/27) 0.09
debut before admission 3% (1/30) 11% (3/27) 0.65
debut after admission 7% (2/30) 19% (5/27) 0.09
Paraclinical findings
CSF WBC (cells/lL) 3261 (1084–4244) 3902 (1436–6663) 0.41
CSF protein (g/L) 2.9 (2.0–7.7) 1.82 (0.87–2.68) 0.01
CSF glucose (mmol/L) 2.2 (0.5–3.2) 1.7 (0.3–3.1) 0.60
CSF/blood glucose ratio 0.28 (0.14–0.38) 0.23 (0.05–0.53) 0.88
Blood WBC (109 cells/L) 15.0 (11.4–19.3) 12.8 (7.3–18.1) 0.29
Platelets (109 cells/L) 216 (169–305) 270 (220–412) 0.12
Blood sodium (mmol/L) 137 (135–139) 135 (134–138) 0.15
Blood glucose (mmol/L) 8.1 (6.6–10.3) 5.7 (3.4–7.2) 0.001
CRP (mg/L) 98 (39–190) 140 (70–178) 0.62
Positive CSF Gram staining 59% (17/29) 65% (15/24) 0.78
Positive CSF culture 97% (34/35) 100% (29/29) 1.00
Positive blood culture 58% (19/33) 50% (11/22) 0.59
Ampicillin non-susceptibility 7% (2/30) 22% (5/23) 0.22
type b 25% (1/4) 31% (4/13) 1.00
type non-b 4% (1/26) 10% (1/10) 0.48
Steroid therapy 10% (3/30) 58% (15/26) 0.0002
Mechanical ventilation 27% (8/30) 20% (5/25) 0.75
Hearing loss 18% (5/28) 13% (3/24) 0.71
Neurological sequelae 4% (1/28) 13% (3/23) 0.31
Death 14% (5/36) 4% (1/29) 0.37
aThree patients had otitis media and pneumonia.
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0.05)]. In addition, 47% (17/36) of adult patients had head-
ache and 47% (7/15) of children <22 months were found to
have a tense fontanelle.
CSF Gram-staining was positive in 60% (32/53) of the sam-
ples, and H. influenzae was cultured from CSF in 98% (63/64)
of cases and from blood in 55% (30/55) of cases. The pres-
ence of a positive blood culture was significantly related to
the primary focus of infection and was more frequently
observed with a lung focus, 100% (8/8) compared with an
otogenic focus, 50% [(9/18), p 0.02], with a sinusitis focus,
40% [(2/5), p 0.03], or with an unknown focus, 46% [(11/24),
p 0.01]. Among children, patients with Hib more frequently
had a positive blood culture than patients without Hib [82%
(9/11) vs. 18% (2/11), respectively, p 0.009].
CSF protein levels were significantly higher in adults than
in children [2.9 g/L (2–7.7) vs. 1.8 g/L (0.9–2.7), respectively,
p 0.01]. Among children, in patients infected with Hib com-
pared with cases with non-Hib, CSF white blood cells were
significantly higher (5870 cells/lL vs. 1783 cells/lL, respec-
tively, p 0.001) and blood platelets (109 cells/L) were signifi-
cantly lower (256 vs. 356, respectively, p < 0.05).
The initial or empiric treatment was primarily intravenous
ceftriaxone and ampicillin for adults or ampicillin and genta-
micin for children. When H. influenzae was isolated from
CSF or blood, antibiotic therapy was changed according to
the results of susceptibility testing and was administered for
10 days (8–14). Adjunctive therapy with corticosteroids was
administered to 32% (18/56) of cases, and was administered
more frequently to children [58% (15/26)] than to adults
[10% (3/30), p 0.002]. Assisted ventilation was required in
24% (13/55) of cases and, among children, patients with Hib
more frequently required assisted ventilation than patients
without Hib [38% (5/13) vs. 0% (0/12), respectively, p 0.04].
Outcome
One child [case fatality rate 4% (1/29)] and five adults [case
fatality rate 14% (5/36)] died as a result of the meningitis epi-
sode. The child was born prematurely at 28 weeks of gesta-
tion, and developed meningitis due to H. influenzae serotype
f 10 weeks after birth, dying 5 days after symptoms
appeared. All five fatal adult cases were of advanced age
(range 83–96 years), were all infected with non-Hib, and died
on day 1, 4, 5, 12 and 16, respectively, after admission.
Table 4 shows the clinical characteristics of the adult cases,
according to whether the patient survived or died. None of
the five fatal adult cases was examined by a physician before
admission, compared with 45% of the surviving cases (13/29,
p 0.1). All five fatal adult cases had altered mental status
upon admission, whereas 60% (17/28) of surviving patients
had altered mental status (p 0.1). Eighty per cent (4/5) of
fatal cases and 7% (2/28) of surviving cases were unconscious
upon admission (p 0.001). Adults who died had more
frequently a positive blood culture than adults who survived
[100% (4/4) vs. 52% (15/29), respectively, p 0.1].
A total of eight among 52 survivors (15%) experienced
hearing loss (five cases had unilateral, and three cases bilat-
eral hearing loss/deafness), and 8% (4/51) experienced neuro-
logical sequelae (two cases with learning deficits and two
cases with ataxia or vestibular dysfunction). Hearing loss was
found in five adults (16%) and three children (10%) upon fol-
low-up examination. No significant association between the
development of sequelae and whether the patient was
infected with Hib or non-Hib was observed (data not
shown).
Multivariate logistic regression analysis showed the pres-
ence of a lung focus as the only significant prognostic factor
TABLE 3. Clinical characteristics of Hib and non-Hib
meningitis among children
Percentage or medians
(25/75 percentiles) Hib (n = 16)
Non-Hib
(n = 13) p-value
Gender (female, %) 50% (8/16) 39% (5/13) 0.71
Age 14 (5–26) 16 (6–77) 0.54
Underlying diseases 0% (0/16) 0% (0/13) ND
Predisposing conditions 0% (0/16) 38% (5/13) 0.01
Focus of infection
Otitis media 38% (6/16)a 54% (7/13) 0.47
Pneumonia 6% (1/16)a 8% (1/13) 1.0
Sinusitis 0% (0/16) 15% (2/13) 0.19
Unknown 63% (10/16) 23% (3/13) 0.06
Examined by a physician
before admission
5% (7/15) 46% (6/13) 1.0
Duration of symptoms
before admission
2 (1–4) 2 (1–5) 0.83
Received antibiotics
before admission
31% (4/13) 23% (3/13) 1.0
Fever before admission 75% (12/16) 69% (9/13) 1.0
Clinical features on admission
Fever (temperature >38C) 100% (13/13) 91% (10/11) 0.46
Body temperature 39.7 (39.1–40.1) 39.5 (38.2–40.1) 0.31
Back rigidity 75% (9/12) 64% (7/11) 0.67
Altered mental status 86% (12/14) 73% (8/11) 0.62
Convulsions 42% (6/14) 15% (2/13) 0.21
debut before admission 21% (3/14) 0% (0/13) 0.22
debut after admission 21% (3/14) 15% (2/13) 1.0
Tense fontanelle 43% (3/7) 50% (4/8) 1.0
Paraclinical findings
CSF WBC (cells/lL) 5870 (4734–8918) 1783 (553–3169) 0.001
CSF protein (g/L) 1.9 (1.0–2.5) 1.7 (0.6–3.2) 0.71
CSF glucose (mmol/L) 1.8 (0.4–3.1) 1.4 (0.2–2.9) 0.81
CSF/blood glucose ratio 0.23 (0.03–0.42) 0.22 (0.05–0.57) 0.75
Blood WBC (109 cells/L) 11.2 (7.2–15.9) 13.5 (6.9–20.7) 0.43
Platelets (109 cells/L) 256 (149–298) 356 (256–462) 0.049
Blood sodium (mmol/L) 134 (131–137) 135 (135–140) 0.055
Blood glucose (mmol/L) 6.4 (4.18.9) 5.1 (3.2–6.4) 0.14
CRP (mg/L) 166 (64–197) 110 (60–161) 0.31
Positive CSF Gram staining 75% (9/12) 50% (6/12) 0.40
Positive CSF culture 100% (16/16) 100% (13/13) ND
Positive blood culture 82% (9/11) 18% (2/11) 0.009
Ampicillin non-susceptibility 31% (4/13) 10% (1/10) 0.33
Steroid therapy 57% (8/14) 58% (7/12) 1.0
Mechanical ventilation 38% (5/13) 0% (0/12) 0.04
Hearing loss 21% (3/14) 0% (0/10) 0.24
Neurological sequelae 8% (1/13) 20% (2/10) 0.56
Death 0% (0/16) 8% (1/13) 0.45
aOne patient had otitis media and pneumonia.
ND, (not determined).
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for an unfavourable outcome (death or sequelae; OR 20, p
0.03, see Table 5).
Discussion
Previous studies have documented a rapid and significant
decrease in the number of cases with Hib meningitis with the
introduction of Hib vaccination in childhood vaccination pro-
grammes. In Denmark the conjugated polysaccharide Hib vac-
cine was introduced in 1993 and a rapid decrease in the
number of cases was observed during the period 1994–1996
[4]. The present study confirms that Hib meningitis has been
almost eliminated in the post-vaccination period 1996–2005,
with less than one case per year, and that less than half of
these cases were vaccine failures. Moreover, no significant
alteration in the annual number of meningitis cases due to
non-Hib was found in Denmark during this period (approxi-
mately four cases per year). Previous studies have generated
conflicting findings, with reports of increased incidence of
TABLE 4. Clinical characteristics of
adults with Haemophilus influenzae
meningitis according to outcome
Characteristics
Non-survivors
(n = 5)
Survivors
(n = 31) p-value
Gender (female, %) 100% (5/5) 58% (18/31) 0.14
Age 86 years (84–92) 59 years (38–67) 0.001
>70 years 5/5 7/31 0.002
>80 years 5/5 1/31 <0.001
Infected by Hib 0% (0/5) 13% (4/31) 1.00
Underlying diseases 0% (0/4) 19% (5/26) 1.00
Predisposing conditions 25% (1/4) 26% (7/27) 1.00
Focus of infection
Otitis media 0% (0/5) 39% (12/31)a 0.15
Pneumonia 40% (2/5) 13% (4/31)a 0.19
Sinusitis 0% (0/5) 10% (3/31) 1.00
Unknown 60% (3/5) 45% (14/31) 0.65
Examined by a physician before admission 0% (0/5) 45% (13/29) 0.13
Duration of symptoms before admission 2 days (1–5) 2 days (2–3) 0.64
Received antibiotics before admission 0% (0/4) 25% (7/28) 0.55
Clinical features on admission
Fever (temp. >38C) 100% (4/4) 79% (19/24) 1.00
Body temperature 39.1C (39.0–39.7) 39.0C (38.1–39.7) 0.58
Back rigidity 60% (3/5) 83% (24/29) 0.27
Altered mental status 100% (5/5) 60% (17/28) 0.14
Convulsions 25% (1/4) 8% (2/26) 0.36
debut before admission 0% (0/4) 4% (1/26) 1.00
debut after admission 25% (1/4) 4% (1/26) 0.25
Steroid therapy 25% (1/4) 8% (2/26) 0.36
Mechanical ventilation 25% (1/4) 27% (7/26) 1.00
Paraclinical findings
CSF WBC (cells/lL) 3012 (2423–3600) 3261 (984–4367) 0.92
CSF protein (g/L) 12.3 (7.7–16.8) 2.7 (1.9–6.4) 0.05
CSF glucose (mmol/L) No data 2.2 (0.5–3.2)
CSF/blood glucose ratio No data 0.28 (0.14–0.38)
Blood WBC (109 cells/L) 21.4 (19.3–23.4) 14.3 (10.9–19.0) 0.10
Platelets (109 cells/L) 359 208 (165–295) 0.19
Blood sodium (mmol/L) 139 137 (135–139) 0.51
Blood glucose (mmol/L) 9.0 (7.3–10.6) 8.1 (6.6–9.9) 0.74
CRP (mg/L) 164 (70–257) 98 (26–171) 0.63
Positive CSF Gram staining 75% (3/4) 56% (14/25) 0.62
Positive CSF culture 100% (5/5) 97% (29/30) 1.00
Positive blood culture 100% (4/4) 52% (15/29) 0.12
Ampicillin non-susceptibility 0% (0/4) 8% (2/26) 1.00
aTwo patients had otitis media and pneumonia.
TABLE 5. Significant prognostic factors for an unfavourable outcomea of Haemophilus influenzae meningitis
Percentage (no./total)
Unfavourable
outcome
(n = 17)
Favourable
outcome
(n = 42)
Univariate
analysis
(OR + 95% CI) p-value
Multivariate
analysis
(OR + 95% CI) p-value
Age (years)b 64 (2–84) 33 (1–59) 1.01 (0.99–1.03) 0.2 1.0 (0.98–1.02) 0.8
Decreased consciousness 88% (14/16) 68% (26/38) 3.2 (0.6–17) 0.16 4.0 (0.5–29) 0.18
Lung focus 35% (6/17) 2% (1/42) 22 (2.4–206) 0.006 20 (1.4–279) 0.03
Otogenic focus 24% (4/17) 48% (20/42) 0.3 (0.1–1.2) 0.1 0.21 (0.04–1.2) 0.09
Positive blood culture 75% (12/16) 47% (17/36) 3.4 (0.9–12) 0.07 1.76 (0.38–8.2) 0.5
aNo data concerning sequelae were available for six patients.
bShown as medians and interquartile range and OR calculated per additional years.
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invasive non-Hib infections with Hib vaccination [8–12] and
reports of no significant increase [3,17,18].
Few studies have investigated the clinical features of
H. influenzae meningitis after introduction of Hib vaccination
[10,19]. In accordance with these studies, we found that
non-Hib was the primary cause of adult H. influenzae menin-
gitis [19] and less frequently the cause in children [3]. The
meningitis patients with predisposing conditions (e.g. CSF
leakage) or with an underlying disease were all infected with
non-Hib, and, confirming previous findings, the presence of a
primary focus of infection was more frequently found in non-
Hib meningitis, with otitis media being the most frequent
focus [10,19]. However, among children infected with Hib,
an ear focus was observed in one-third of cases, whereas no
focus was found in the remaining two-thirds of cases.
Interestingly, infection with Hib differed from infection with
non-Hib in children, with a more frequent presence of
bacteraemia, higher recruitment of cells to the CSF, and a
greater need for mechanical ventilation in children infected
with Hib compared with non-Hib.
The majority of patients presented with classical signs of
meningitis upon admission (i.e. decreased consciousness,
nuchal rigidity) and meningitis was correctly diagnosed by
the admitting physician in most cases. The case fatality rate
of H. influenzae meningitis was low, corresponding to previ-
ous studies in adults [19] and children [20], indicating that
H. influenzae meningitis has a better prognosis, in comparison
with Streptococcus pneumoniae meningitis, according to a pre-
vious study [21]. Moreover, the presence of an otogenic
focus was associated with a better prognosis, while the pres-
ence of a primary lung focus was associated with a poorer
prognosis, confirming our findings concerning pneumococcal
meningitis [21].
In conclusion, H. influenzae meningitis has become a rare
disease primarily due to the continuously high Hib vaccina-
tion coverage among children [22], with no signs of sero-
type replacement and no change in morbidity of the
disease. Meningitis due to a non-b serotype was frequently
found in cases with predisposing conditions (CSF leakage
or a respiratory tract infection focus). The prognosis of
H. influenzae meningitis is better than that of pneumococcal
meningitis.
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